A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer

BJU International

Volumn 111, Issue 2, 2013, Pages 221-232

  Kyrdalen, Anne E ^a   Dahl, Alv A ^a   Hernes, Eivor ^a   Småstuen, Milada Cvancarova ^a   Fosså, Sophie D ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

adverse effects; curative treatment; global quality of life; medication for erectile dysfunction; neuroticism

Indexed keywords

GONADORELIN; PAPAVERINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRIEF SEXUAL FUNCTION INVENTORY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CONTROLLED STUDY; ENTEROPATHY; ERECTILE DYSFUNCTION; EXPANDED PROSTATE CANCER INDEX COMPOSITE; FECES INCONTINENCE; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE;

AGED; ANDROGEN ANTAGONISTS; ANXIETY DISORDERS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; ERECTILE DYSFUNCTION; FECAL INCONTINENCE; GONADOTROPIN-RELEASING HORMONE; HEALTH SURVEYS; HUMANS; INTESTINAL DISEASES; LIBIDO; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; URINARY INCONTINENCE;

EID: 84873108231     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11198.x     Document Type: Article

References (39)

1. Bhatnagar V, Stewart ST, Huynh V, Jorgensen G, Kaplan RM,. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis 2006; 9: 136-146
2. Wilt TJ, MacDonald R, Rutks I, Shamilyan TA, Taylor BC, Kane RL,. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 435-448
3. Huang GJ, Sadetsky N, Penson DF,. Health Related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 2010; 183: 2206-2212
4. Penson DF, Feng ZD, Kuniyuki A, et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 2003; 21: 1147-1154
5. Madalinska JB, Essink-Bot ML, de, Koning HJ, Kirkels WJ, van der, Maas PJ, Schroder FH,. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19: 1619-1628
6. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. NEJM 2008; 358: 1250-1261
7. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 3979-3986
8. Pardo Y, Guedea F, Aguilo F, et al. Quality-of-Life Impact of Primary Treatments for Localized Prostate Cancer in Patients Without Hormonal Treatment. J Clin Oncol 2010; 28: 4687-4696
9. Reeve BB, Potosky AL, Willis GB,. Should function and bother be measured and reported separately for prostate cancer quality-of-life domains? Urology 2006; 68: 599-603
10. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. NEJM 2002; 347: 790-796
11. Clark JA, Rieker P, Propert KJ, Talcott JA,. Changes in quality of life following treatment for early prostate cancer. Urology 1999; 53: 161-168
12. Namiki S, Kwan L, Kagawa-Singer M, Terai A, Arai Y, Litwin MS,. Urinary quality of life after treatment for localized prostate cancer: a prospective crosscultural study between Japanese and American men. J Urol 2008; 179: 108
13. Namiki S, Kwan L, Kagawa-Singer M, et al. Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. Prostate Cancer Prostatic Dis 2008; 11: 298-302
14. Lilleby W, Fossa SD, Waehre HR, Olsen DR,. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 735-743
15. Costa PT, Mccrae RR,. Neuroticism, Somatic Complaints, and Disease-Is the Bark Worse Than the Bite. J Pers 1987; 55: 299-316
16. Mccrae RR, Costa PT,. Personality in Adulthood. A Five-Factor Theory Perspective, 2nd edn. New York, USA: Guilford Press, 2003
17. Lahey BB,. Public health significance of neuroticism. Am Psychol 2009; 64: 241-256
18. Grov EK, Fossa SD, Bremnes RM, et al. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncol 2009; 48: 842-849
19. Steinsvik AS, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fosså SD,. Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Int 2012; 109: 1366-1374
20. Stephenson RA, Mori M, Hsieh YC, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the surveillance, epidemiology, and end results prostate cancer outcomes study. J Urol 2005; 174: 646-650
21. Namiki S, Kwan L, Kagawa-Singer M, Arai Y, Litwin MS,. The effect of erectile function on the use of phosphodiesterase-5 inhibitors after radical prostatectomy in Japanese and US men. Urology 2008; 71: 901-905
22. Seftel AD, Buvat J, Althof SE, et al. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res 2009; 21: 240-248
23. Hernes E, Kyrdalen A, Kvale R, et al. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU Int 2010; 105: 805-811
24. D'Amico AV, Whittington R, Malkowicz SB, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166: 2185-2188
25. Barry MJ, Fowler FJ, Oleary MP, et al. The American-urological- association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-1557
26. Barry MJ, Williford WO, Chang YC, et al. Benign prostatic hyperplasia specific health-status measures in clinical research-how much change in the American-urological-association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients. J Urol 1995; 154: 1770-1774
27. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG,. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899-905
28. Oleary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697-706
29. Mykletun A, Dahl AA, O'Leary MP, Fossa SD,. Assessment of male sexual function by the brief sexual function inventory. BJU Int 2006; 97: 316-323
30. Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fossa SD,. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 2007; 52: 1438-1447
31. Ware JE, Kosinski M, Keller SD,. A 12-item short-form health survey-construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233
32. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. J Clin Epidemiol 1998; 51: 1171-1178
33. Eysenck HJ, Eysenck SBG,. Manual of the EPQ. London: Hodder and Stoughton, 1975
34. Eysenck SBG, Tambs K,. Cross-cultural-comparison of personality-Norway and England. Scand J Psychol 1990; 31: 191-197
35. Sprangers MAG, Schwartz CE,. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 1999; 48: 1507-1515
36. Donohoe JE,. To what extent can response shift theory explain the variation in prostate cancer patients' reactions to treatment side-effects? A review. Qual Life Res 2011; 20: 161-167
37. Al Shaiji T, Domes T, Brock G,. Penile rehabilitation following treatment for prostate cancer: an analysis of the current state of the art. Can Urol Assoc J 2009; 3: 37-48
38. Korfage IJ, Essink-Bot ML, Borsboom GJJM, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005; 116: 291-296
39. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. Br Med J 2009; 339: b4817. doi: 10.1136/bmj.b4817